Barostim therapy—an innovative neuromodulation device system developed by CVRx to treat heart failure with reduced ejection fraction—involves significant costs associated with the specialized implantable hardware and surgical implantation procedures. The overall hospital and procedural costs typically range between $40,000 and $70,000, influenced by medical facility fees, surgical expenses, and geographic location. Recognizing its clinical value, major healthcare systems and reimbursement bodies like Medicare have established dedicated inpatient MS-DRG and outpatient Ambulatory Payment Classification (APC) codes providing substantial coverage (averaging between $43,000 and $45,000 in institutional payments), which significantly reduces direct out-of-pocket financial burdens for eligible patients.